维利西呱有哪几个版本?分别多少钱?

Veliciguat is an innovative drug for the treatment of heart failure. It exists in multiple versions and strengths around the world, and prices vary depending on region and strength. The drug has been officially launched in China and has been included in the medical insurance catalog, providing more treatment options for domestic patients. This article will provide a detailed introduction to the different versions of viliciguat, price information for each version, and availability in the Chinese market.

What versions of Veliciguat are there

There are multiple versions around the world, mainly produced by pharmaceutical companies in different countries. These versions differ in size and packaging, but the core ingredients and therapeutic benefits are essentially the same.

German original research version

The original research drug produced by Bayer in Germany is the standard version of Vericiguat, with the trade name Verquvo. This version is packaged in aluminum-plastic blister packs and is available in three specifications: 2.5mg, 5mg and 10mg, respectively corresponding to the needs of different treatment stages.

Japanese version

Viliciguat sold in the Japanese market is also produced by Bayer, but the packaging specifications are different from the international version. The Japanese version provides large format packaging of 100 pills, which is more suitable for patients taking long-term medication.

Chinese version

The trade name of Veliciguat launched in China is Weiketong, which has been approved by the State Food and Drug Administration. This version is consistent in quality and efficacy with the original German version, and is available in standard packaging of 7 tablets/box.

Understanding the different versions of veliciguat can help patients choose the appropriate medication regimen based on their needs.

How much do different versions of Vilicigua cost?

The price of Viliciguat varies depending on versions, specifications and regional differences. The following is the latest price information for the main versions. The prices are for reference only.

German version price

The price of the original drug produced by Bayer in Germany is relatively high. The 2.5mg*28-capsule package is priced at approximately US$343; the 5mg*98-capsule package is approximately US$640; the 10mg*98-capsule package is approximately US$644. The unit price of large-size packaging is more economical.

Japanese version price

The price of Vericiguat sold in the Japanese market is relatively moderate, about US$151 for 2.5mg*100 pills; about US$254 for 5mg*100 pills; and about US$413 for 10mg*100 pills. 100 capsules are suitable for patients who require long-term treatment.

Price of the Chinese version

Vicoton, which is launched in China, has been included in the medical insurance, and the patient’s out-of-pocket payment has been significantly reduced. The specific price varies depending on local medical insurance policies. It is recommended to consult the local hospital or medical insurance department.

Price information may fluctuate with exchange rates and market conditions. It is recommended to confirm the latest pricing before purchasing.

Veliciguat’s launch and medical insurance status in China

Veliciguat has been officially launched in China and has been included in the national medical insurance directory, which has greatly improved the accessibility of the drug.

Marketing status

China’s State Food and Drug Administration approved the marketing of Veliciguat in 2022, with the trade name Weiketong. The drug is suitable for patients with heart failure with reduced ejection fraction and is available in three strengths: 2.5mg, 5mg and 10mg.

Medical insurance coverage

Veliciaguat has been included in the 2023 National Medical Insurance Drug Catalog, and the reimbursement ratio varies by region. Medical insurance coverage has significantly reduced the financial burden on patients, allowing more patients to obtain this innovative treatment.

Purchase Channels

Patients can purchase Vericiguat in pharmacies of major hospitals with a doctor’s prescription. The reimbursement process of designated medical insurance institutions is more convenient, so it is recommended to give priority.

The launch of Veliciguat in China and its inclusion in medical insurance provide an important treatment option for patients with heart failure.